Skip to content

Cannabis research: what the evidence shows

A widely used plant studied across pain, anxiety, sleep, and its interactions with mental health.

State of the evidence

Synthesized

Synthesized from 23 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Cannabis, marijuana, THC, tetrahydrocannabinol, then ranked by relevance.

The research on cannabis is broad and mostly concerns risks rather than benefits. The most consistent finding is that cannabis use is associated with an increased risk of psychosis and psychotic symptoms, with evidence of a dose-response relationship and greater risk from high-potency products and early adolescent use; reviews describe cannabis as a component cause rather than a sufficient or necessary cause. Experimental work suggests THC can produce transient psychotic and anxiety effects while CBD may buffer some of them, and observational studies link early or heavy use to poorer cognition and to relapse in people with psychotic or bipolar disorders. The main caveats are that most human evidence is observational and cannot establish causation, samples are often small or single-population, and long-term durability and dose thresholds remain poorly characterized.

Evidence by study

Direction is which way each study's own result points, not our rating of the study. All 25 matching studies were reviewed; the 23 that directly address the question are shown here.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
Causal association between cannabis and psychosis: examination of the evidence 2004 review Supports Concludes that cannabis use confers an overall twofold increase in relative risk for later schizophrenia and could account for about 8% of incidence if causal, acting as a component rather than sufficient or necessary cause.
Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. 2018 review Mixed Describes phytocannabinoids as involved in central and peripheral pathophysiological processes including food intake, inflammation, pain, sleep, and neurological and psychiatric illness, while noting therapeutic and recreational uses.
High-potency cannabis and the risk of psychosis 2009 case-control study 454 Supports First-episode psychosis cases were more likely to be daily users (OR 6.4), to have used over 5 years (OR 2.1), and among users 78% of cases versus 37% of controls used high-potency cannabis (OR 6.8).
Psychiatric effects of cannabis 2001 review Opposes Argues that cannabis carries risks of dependence and short-lived psychotic states after heavy use, and that people with schizophrenia are especially vulnerable, with cannabis provoking relapse and aggravating symptoms.
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment 2012 randomized controlled trial 48 Supports Pre-treatment with 600 mg CBD reduced THC-elicited paranoia and clinically significant positive psychotic symptoms (OR 0.22) and mitigated THC-induced episodic memory impairment.
Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing 2009 double-blind randomized placebo-controlled crossover trial 15 Mixed THC increased anxiety, intoxication, sedation, and psychotic symptoms and increased skin conductance responses to fearful faces, while CBD showed a trend toward reduced anxiety and dampened limbic activation.
Beyond THC: The New Generation of Cannabinoid Designer Drugs 2011 review Opposes Argues that synthetic cannabinoid Spice products pose serious health risks including psychosis and death and are particularly appealing and dangerous to young and drug-naive users.
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug 2006 review Supports Argues that cannabidiol has anxiolytic and antipsychotic-like properties and may be a safe, well-tolerated alternative treatment for schizophrenia, based on animal, healthy-volunteer, and preliminary clinical reports.
Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. 2012 review Opposes Argues that synthetic cannabinoids in herbal marijuana alternatives and other novel psychoactive substances, often perceived as safe, can cause adverse effects ranging from minimal to life-threatening.
Traditional marijuana, high‐potency cannabis and synthetic cannabinoids: increasing risk for psychosis 2016 review Opposes Concludes that cannabis is a component cause of psychosis with a dose-response relationship, that high-potency cannabis and synthetic cannabinoids carry the greatest risk, and that risks are magnified by early adolescent use and include cognitive impairment.
Gone to Pot – A Review of the Association between Cannabis and Psychosis 2014 review Opposes Concludes that cannabis may be a component cause of psychosis, citing acute and persistent psychotic-like effects, dose-related adolescent risk, and exacerbation of symptoms and relapse in established psychotic disorders, while noting the association meets many but not all causality criteria.
Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study 2011 observational cohort 1923 Supports Incident cannabis use increased risk of later incident psychotic symptoms (adjusted OR 1.9) and continued use increased risk of persistent psychotic symptoms (OR 2.2) over a 10-year follow-up.
Cannabis use before age 15 and subsequent executive functioning 2011 observational cross-sectional study 148 Opposes Early-onset chronic users (before age 15) performed significantly worse than controls and late-onset users on sustained attention, impulse control, and executive functioning tasks.
Impact of Cannabis Use on Time to Psychiatric Rehospitalization in Young Adults With Bipolar and Psychotic Disorders: A Survival Analysis. 2026 historical cohort 200 Opposes Cannabis use at admission was associated with increased psychiatric readmission risk within the first month (HR 2.8) and by 3 months (HR 1.9), becoming nonsignificant at 6 months.
The Artifact Hypothesis: Deconstructing Schizophrenia Through the Lens of Prohibition, Adulterated Cannabis, and Neurodevelopmental Psychopathology 2026 theoretical or philosophical paper Mixed Argues that a significant proportion of youth schizophrenia diagnoses may be a diagnostic artifact of prohibition-era policies and high-potency adulterated cannabis, and advocates dimensional models of psychopathology.
HPLC ‐ UV quantitation of synthetically derived THC , THCP , and HHC isomers in commercial vaping liquids and edibles (2019–2024) 2026 analytical chemistry study Unclear Reports that synthetically derived THC products contained variable and sometimes very high levels of THC isomers, with total THC isomer content of 25-96% w/w in vaping liquids and dabs and up to 791 mg per gummy.
Cue-elicited prefrontal gamma-aminobutyric acid (GABA) dynamics in cannabis use disorder. 2026 case-control study 41 Mixed Overall prefrontal GABA+ levels were similar between groups, but the cannabis use disorder group showed increased GABA+ during cannabis cue reactivity compared with neutral cues.
Prenatal Δ9-tetrahydrocannabinol exposure rewires glucocorticoid-hippocampal crosstalk and impairs memory under stress in adolescent rat offspring. 2026 experimental animal study Opposes Prenatal THC exposure in rats produced stress-related search strategies, delayed learning, and impaired memory with elevated glucocorticoids and altered hippocampal markers, and metyrapone rescued memory performance.
Cognitive Outcomes among Cannabis Users with and without a History of Polysubstance Use 2026 observational study Mixed Polysubstance users scored 2.41 points higher on planning than cannabis-only users, while greater daily cannabis quantity was associated with blunted stress cortisol response, lower impulsivity and memory scores, and higher risk aversion.
Cannabis Use Interacts With Psychosis Vulnerability in Borderline Personality Disorder: La consommation de cannabis interagit avec la vulnérabilité à la psychose dans le trouble de la personnalité limite 2026 cross-sectional clinical study 79 Mixed Cannabis use moderated the association between psychotic-like experiences and BPD symptom severity, strengthening it at higher cannabis use, with the lowest BPD symptoms among those low in psychotic-like experiences and high in cannabis use.
769. Can the genetic of liver enzyme involved in THC metabolism tell us who are the cannabis users at greater risk of psychosis? 2026 genetic association study Mixed A genetic risk score for CYP3A4 expression was associated with differences in paranoia scores and likelihood of psychotic-like experiences among cannabis users, suggesting faster THC metabolism may reduce psychotomimetic effects.
Cannabis Is a Psychedelic, and a Beneficial One at That - The Overlooked Cannabinoid Path Into Altered Consciousness 2026 theoretical or philosophical paper Mixed Argues that cannabis is phenomenologically psychedelic and medically useful in several established contexts while carrying risks including anxiety, cognitive impairment, psychosis vulnerability, and cannabis use disorder, with effects shaped by dose, biology, expectations, and setting.
"Cannabis Green Wave" versus "Nicotine Freeze": the regulatory paradox of cannabis liberalization and nicotine prohibition. 2026 theoretical or philosophical paper Mixed Argues that cannabis liberalization and nicotine restriction reflect a regulatory double standard driven by ideology rather than toxicology, and proposes a consistent risk-proportionate harm-reduction paradigm across psychoactive substances.

Points of agreement

  • Multiple reviews and cohort studies agree that cannabis use is associated with increased risk of psychosis and psychotic symptoms, with a dose-response pattern.
  • High-potency cannabis and early adolescent onset are consistently identified as amplifying psychosis and cognitive risks.
  • Experimental and review evidence indicates THC can produce transient psychotic, anxiety, and memory-impairing effects, while CBD may attenuate some of these.
  • Observational and clinical studies link cannabis use to relapse or symptom exacerbation in people with psychotic or bipolar disorders.
  • Reviews and essays agree that cannabis has both established therapeutic uses and meaningful psychiatric and cognitive risks.

Conflicts

  • Some work frames cannabis as a component cause of psychosis, while a theoretical paper argues that a substantial share of youth schizophrenia diagnoses may be a diagnostic artifact of prohibition and adulterated high-potency products.
  • One clinical study found cannabis use associated with lower BPD symptoms among individuals with low psychotic-like experiences, contrasting with the broader risk narrative.
  • A genetic study suggests faster THC metabolism may reduce psychotomimetic effects, implying individual differences in vulnerability that complicate uniform risk claims.
  • A cognitive study reported unexpected associations, including higher planning scores in polysubstance users and lower impulsivity with greater cannabis quantity, which run against simple harm expectations.

Gaps

  • Most human evidence is observational, so causal direction and confounding by genetic and environmental factors remain unresolved.
  • Durability of cognitive and psychiatric effects after cessation is not well characterized.
  • Dose thresholds and the specific contribution of CBD-to-THC ratios in real-world products are unclear.
  • Small samples in experimental and clinical studies limit generalizability.
  • Populations such as adolescents, pregnant individuals, and psychiatric patients are understudied in controlled designs.
  • Long-term effects of synthetic cannabinoids and novel THC isomers are largely unknown.
Browse these studies in the library

Common questions

What does the research agree on about cannabis?
  • Multiple reviews and cohort studies agree that cannabis use is associated with increased risk of psychosis and psychotic symptoms, with a dose-response pattern.
  • High-potency cannabis and early adolescent onset are consistently identified as amplifying psychosis and cognitive risks.
  • Experimental and review evidence indicates THC can produce transient psychotic, anxiety, and memory-impairing effects, while CBD may attenuate some of these.
  • Observational and clinical studies link cannabis use to relapse or symptom exacerbation in people with psychotic or bipolar disorders.
  • Reviews and essays agree that cannabis has both established therapeutic uses and meaningful psychiatric and cognitive risks.
Where do studies on cannabis conflict?
  • Some work frames cannabis as a component cause of psychosis, while a theoretical paper argues that a substantial share of youth schizophrenia diagnoses may be a diagnostic artifact of prohibition and adulterated high-potency products.
  • One clinical study found cannabis use associated with lower BPD symptoms among individuals with low psychotic-like experiences, contrasting with the broader risk narrative.
  • A genetic study suggests faster THC metabolism may reduce psychotomimetic effects, implying individual differences in vulnerability that complicate uniform risk claims.
  • A cognitive study reported unexpected associations, including higher planning scores in polysubstance users and lower impulsivity with greater cannabis quantity, which run against simple harm expectations.
What is still unknown about cannabis?
  • Most human evidence is observational, so causal direction and confounding by genetic and environmental factors remain unresolved.
  • Durability of cognitive and psychiatric effects after cessation is not well characterized.
  • Dose thresholds and the specific contribution of CBD-to-THC ratios in real-world products are unclear.
  • Small samples in experimental and clinical studies limit generalizability.
  • Populations such as adolescents, pregnant individuals, and psychiatric patients are understudied in controlled designs.
  • Long-term effects of synthetic cannabinoids and novel THC isomers are largely unknown.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Cannabis, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Cannabis or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

Latest monthly recap: September 2026 →

2,858 articles · 516 from the last two years · 4,844,000 participants across 1,345 studies reporting sample size

Common study designs

review 414 case study 98 systematic review 113 observational cohort 225 randomized controlled trial 123

Cannabis research by condition

Data updated

Studies whose primary subject is both Cannabis and the condition, with reviews counted by the study design extracted from each abstract. Registered trials are from ClinicalTrials.gov. This maps how much research exists, not how well anything works.

Cannabis research by condition: studies, meta-analyses and systematic reviews, registered clinical trials, the highest trial phase, and studies from the last two years. Most studies first.
Condition Studies Meta-analyses and systematic reviews Registered trials Highest phase From the last two years
Addiction 87 studies 4 meta-analyses and systematic reviews 34 registered trials up to Phase 4 12 from the last two years
Anxiety 78 studies 9 meta-analyses and systematic reviews 20 registered trials up to Phase 2/3 18 from the last two years

Research volume by year

Compare topics →

1,874 studies whose primary subject is cannabis since 2002

Studies about cannabis per year, 2002 to 2026, peaking at 208 in 2026 Bar chart: one bar per year, taller where more studies were published that year. 0 150 300 2005 2010 2015 2020 2025
2026 is partial
Show the numbers
Studies about cannabis per year, 2002 to 2026, peaking at 208 in 2026
Year Studies
2002 15
2003 9
2004 27
2005 25
2006 33
2007 47
2008 48
2009 51
2010 64
2011 67
2012 52
2013 31
2014 49
2015 69
2016 65
2017 78
2018 130
2019 79
2020 92
2021 112
2022 133
2023 166
2024 98
2025 126
2026 208

Research

Synthesize the evidence → Search all →

Do consumer-facing “Indica,” “Sativa,” and “Hybrid” labels predict cannabis composition or effects? A systematic review

Journal of Cannabis Research October 24, 2026 Gabriel Zoobi, Mackenzie Marco, Khalid J. Foraida et al.

Abstract: Background: Consumer- and patient-facing cannabis products are commonly labeled “indica,” “sativa,” or “hybrid” to signal expected composition or effects. We systematically reviewed whether these labels predict cannabis composition, animal effects, or human outcomes. Methods: We last searched PubMed/MEDLINE, Europe PMC, PubPsych, OpenAlex, and ClinicalTrials.gov, supplemented by...

DOI: 10.1186/s42238-026-00528-3 (opens in new tab)

Impact of cannabis use and cannabis composition on formal thought disorder and related brain networks: An fMRI study in 51 patients with schizophrenia

Schizophrenia Research October 23, 2026 Thomas Bernabeu, Mathilde Argote, Antony Citterio‐Quentin et al.

BACKGROUND: Formal thought disorder (FTD) is a core dimension of schizophrenia, which has been associated in previous studies with increased brain functional connectivity between temporal gyri and striatal regions as measured with fMRI. Cannabis use is highly prevalent in schizophrenia population as compared with the general population and, in the context of elevated...

DOI: 10.1016/j.schres.2026.10.013 (opens in new tab)

The influence of acute cannabis smoking on cigarette and e-cigarette puff topography and subjective effects in people who use cannabis, cigarettes, and e-cigarettes.

Experimental and Clinical Psychopharmacology October 22, 2026 C Austin Zamarripa, Tory R Spindle, Dustin C Lee et al.

Co-use of smoked/vaped tobacco and cannabis is increasing with expanding legalization, yet controlled clinical studies examining mechanisms underlying co-use remain limited. This study evaluated whether acute smoked cannabis influences subsequent use ("chasing") of combustible cigarettes and e-cigarettes among people who use cannabis, cigarettes, and e-cigarettes. Twenty adults who used...

DOI: 10.1037/pha0000882 (opens in new tab) Full text (opens in new tab)

Exploring Perceived Relationships Between Cannabis Use and Mental Health Symptoms Among Emerging Adults at High Risk for Psychosis: A Qualitative Study

Emerging Adulthood October 19, 2026 Kayla K. Giorlando, Jennifer E. Merrill, Ethan Moitra et al.

Cannabis use among emerging adults has reached historically high levels, yet there is growing evidence that cannabis use during this developmental period may exacerbate existing psychopathology and increase risk of developing schizophrenia-spectrum disorders. This qualitative study examines perceptions of how cannabis use impacts psychiatric symptoms among twenty emerging adults (ages 18–24) at...

DOI: 10.1177/21676968261499756 (opens in new tab)

From cytotoxicity to clinical safety: Product-specific evidence and justified extrapolation for Cannabis and Psilocybe preparations

Zenodo (CERN European Organization for Nuclear Research) October 19, 2026 Kimio Shiraishi preprint

This preprint presents a focused critical narrative review of how safety findings for Cannabis and Psilocybe preparations are transferred across products, formulations, exposures, test systems, populations, and conditions of use. The central question is not whether safety evidence can ever be extrapolated, but when such extrapolation is justified and what information is needed to support it....

DOI: 10.5281/zenodo.23484000 (opens in new tab)

Adolescent-onset regular cannabis use is associated with altered neural and behavioural responses during anticipation and feedback of monetary reward and loss

Psychopharmacology October 17, 2026 Giada Lombardi, Grace Blest‐hopley, Martina Maria Tarantini et al.

RATIONALE: Regular cannabis use has been associated with alterations in reward-related neural processes, yet findings remain inconsistent and the relationship between neural activity and behavioural performance is not fully understood. OBJECTIVES: The present study aimed to characterise neural and behavioural correlates of reward processing in regular cannabis users (CU) compared with matched...

DOI: 10.1007/s00213-026-07183-9 (opens in new tab) Full text (opens in new tab)

Progressive weight loss is attenuated by THC treatment in rats with activity-based anorexia.

Physiology & Behavior October 15, 2026 Savoya S Joyner, Lisa A Eckel

Anorexia nervosa (AN) is a severe psychiatric disorder with limited effective pharmacological treatments. Given the role of the endocannabinoid system (ECS) in regulating energy balance and its possible involvement in AN pathophysiology, cannabinoid-based interventions may hold therapeutic potential. Using the preclinical activity-based anorexia (ABA) model, we investigated whether...

DOI: 10.1016/j.physbeh.2026.115448 (opens in new tab) Full text (opens in new tab) Activity-based anorexia Cannabinoids Eating disorders Female rats +1

Is it safe-and ethical-to prescribe THC to youth?

Psychopharmacology October 14, 2026 José Alexandre S. Crippa, Jaime E. C. Hallak

The medical use of cannabis-derived products in children and adolescents has expanded beyond established indications for purified cannabidiol (CBD), with increasing investigation of CBD-rich extracts containing Δ9-tetrahydrocannabinol (THC) for neuropsychiatric conditions. Although preliminary studies suggest potential symptomatic benefits, the evidence remains limited by small samples,...

DOI: 10.1007/s00213-026-07186-6 (opens in new tab) Full text (opens in new tab)

Acute Ultra Low Dose THC Attenuates Anxiety-Like Behavior in a Mouse Model for Major-Depressive Disorder

Journal of Molecular Neuroscience October 12, 2026 Meitar Grad, Hadas Volkov, Noam Shomron

Abstract Major depressive disorder (MDD) is a prevalent psychiatric disorder, and is a leading cause of disability worldwide. Current treatments for MDD entail many side effects, and include a lag until the onset of therapeutic effects. The current hypotheses as for the etiology of MDD revolve around the monoamine hypothesis and the plasticity and neurodegeneration hypothesis. According to the...

DOI: 10.1007/s12031-026-02597-8 (opens in new tab) Full text (opens in new tab)

Maternal edible THC consumption alters offspring neurodevelopment and emotional behavior in rhesus macaques.

Neurobiology of Disease October 6, 2026 Rahul J D'Mello, Lyndsey E Shorey-Kendrick, Joshua A Karpf et al.

Prenatal cannabis exposure is associated with adverse offspring outcomes including altered neurodevelopment. However, there is insufficient evidence to establish a direct association. We sought to determine the impact of chronic prenatal delta-9-tetrahydrocannabinol (THC) exposure on offspring neurodevelopment and emotional behavior in a translational rhesus macaque model. Animals were divided...

DOI: 10.1016/j.nbd.2026.107640 (opens in new tab) Full text (opens in new tab) Cannabis THC Behavior Brain +2

Clinical trials

All Cannabis trials →